# US 2025/0154598 A1 · Non-coding rna for detection of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154598 A1
- Document ID: US20250154598A1
- Status: Published application
- Kind: A1
- Application number: 18/752,640
- Filed: 2024-06-24
- Published: 2025-05-15
- Earliest claimed: 2017-11-12
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Hani Goodarzi
- Web page: https://patentgrep.com/patent/US20250154598A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/485: {involving kinase}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

The present disclosure relates generally to detection on non-coding RNA molecules in a sample or diagnosis of subject based upon detection or quantification of non-coding nucleic acid sequences in a sample, specifically to identify and use of molecular biomarkers for cancer including breast cancer.

## Claims

### Claim 1

A method of diagnosing a subject with a benign, pre-malignant, or malignant hyperproliferative cell comprising:
detecting the presence, absence, and/or quantity of at least one orphan non-coding RNA (oncRNA) or functional fragment thereof in a sample from the subject using one or more probe specific for oncRNA.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a human diagnosed with or suspected as having a breast cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the step of detecting comprises:
a) contacting the sample with one or a plurality of probes specific for the at least one oncRNA or functional fragment thereof, and normalizing the quantity in the sample with a measurement taken from a control sample;
b) contacting the total RNA of the sample to at least one probe complementary to one or a combination of nucleic acid sequences comprising any of the sequences in Tables 1, 2, and/or 3; and/or
c) using a chemiluminescent probe, fluorescent probe, and/or fluorescence microscopy.

### Claim 4 (depends on 1)

The method of claim 1 further comprising exposing a sample from a subject to at least one probe specific for one or a combination of oncRNAs chosen from: SEQ ID NO: 1 through SEQ ID NO:201 or one or a combination of oncRNAs that comprise at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence homology to any nucleic acid of Tables 1, 2, and/or 3.

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least one oncRNA is T3p or a functional fragment thereof.

### Claim 6 (depends on 1)

The method of claim 1, further comprising correlating the amount of at least one oncRNA or homologous sequence thereof in the sample to the probability or likelihood the subject has a benign, pre-malignant, or malignant growth, relative to a measurement of the amount of at least one oncRNA or homologous sequence thereof in a control sample.

### Claim 7 (depends on 1)

The method of claim 1, wherein the benign, pre-malignant, or malignant hyperproliferative cell is from breast tissue.

### Claim 8 (depends on 1)

The method of claim 1, wherein the sample comprises:
a) blood or serum from a subject;
b) RNA taken from a culture of cells seeded or inoculated by at least one cell from a subject;
c) human tissue sample comprising a tissue or liquid sample from a plasma, serum or blood draw, brushing, biopsy, or surgical resection of a subject; or
d) a cell that is freshly obtained, formalin fixed, alcohol-fixed and/or paraffin embedded.

### Claim 9 (depends on 1)

The method of claim 1 further comprising culturing at least one biopsy from the subject with a culture medium under conditions and for a time period sufficient to grow at least one cell from a subject's breast tissue.

### Claim 10 (depends on 1)

The method of claim 1, wherein the step of measuring the quantity of at least one oncRNA or a functional fragment thereof in a sample comprises one or a combination of: digitally imaging a sample; exposing a sample to a known amount of labeled antibody specific for an epitope of oncRNA or a functional fragment thereof, exposing a sample to one or a plurality of dyes of specific for oncRNA or a functional fragment thereof, exposing a sample to at least one labeled probe complementary to a sequence of the oncRNA or a functional fragment thereof, exposing a sample to chromatography, isolating total RNA of a sample and exposing the total RNA to sequencing analysis and/or exposing the sample to mass spectrometry, and, optionally, further comprising analyzing morphology of cells from the sample.

### Claim 11 (depends on 1)

The method of claim 1, comprising:
a) contacting one or a plurality of probes specific for the at least one oncRNA or functional fragment thereof with the sample;
b) quantifying the presence, absence, or quantity of the at least one oncRNA or functional fragment thereof in the sample;
c) calculating one or more scores based upon the presence, absence, or quantity of the at least one oncRNA or functional fragment thereof;
d) correlating the one or more scores to the presence, absence, or quantity of the at least one oncRNA or functional fragment thereof, such that, if the amount of the at least one oncRNA or functional fragment thereof is greater than the quantity of the at least one oncRNA or functional fragment thereof in a control sample, the correlating step comprises diagnosing the subject with the benign, pre-malignant, or malignant hyperproliferative cell.

### Claim 12

A method of detecting a cancer cell in a subject comprising:
detecting whether a oncRNA is present in a sample of the subject by contacting the sample with an amount of one or a combination of probes complementary to one or a combination of oncRNA sequences.

### Claim 13 (depends on 12)

The method of claim 12, wherein the step of detecting is preceded by a step of obtaining RNA from the sample of the subject.

### Claim 14 (depends on 12)

The method of claim 12 further comprising:
calculating one or more scores based upon the presence, absence, or quantity of one oncRNA and/or a homologous sequence thereof; and
correlating the one or more scores to the presence, absence, or quantity of oncRNA and/or functional fragment thereof, such that, if the amount of oncRNA and/or functional fragment thereof is greater than the quantity of oncRNA and/or functional fragment thereof in a control sample; or, if the amount of oncRNA and/or functional fragment thereof is substantially equal to the quantity of oncRNA and/or functional fragment thereof in a sample taken from a subject known to have cancer then the subject is diagnosed as having cancer.

### Claim 15 (depends on 12)

The method of claim 12 further comprising detecting a presence or quantifying two or more oncRNAs chosen from those nucleic acid sequences of Tables 1, 2, and/or 3 or one or combination of nucleic acids sequences that comprise at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence homology to any of the sequences of Tables 1, 2 and/or 3.

### Claim 16 (depends on 12)

The method of claim 12, wherein the sample:
a) is a human tissue sample comprising a tissue from a serum or plasma or blood draw, brushing, biopsy, or surgical resection of the subject;
b) comprises total RNA from a cell that is freshly obtained, formalin fixed, alcohol-fixed and/or paraffin embedded; or
c) is plasma, blood or serum.

### Claim 17 (depends on 12)

The method of claim 12, wherein the probe is complementary to an oncRNA sequence that is T3p.

### Claim 18

A method of treating a subject in need thereof diagnosed with or suspected of having breast cancer, comprising:
(a) contacting one or a plurality of probes specific for one or a combination of oncRNAs and/or a homologous sequence thereof with a sample;
(b) quantifying the presence, absence or amount of oncRNA and/or a homologous sequence thereof in the sample;
(c) calculating one or more scores based upon the presence, absence, or quantity of oncRNA and/or a homologous sequence thereof;
(d) correlating the one or more scores to the presence, absence, or quantity of oncRNA and/or a homologous sequence thereof, such that, if the amount of oncRNA and/or a homologous sequence thereof is greater than the quantity of oncRNA and/or a homologous sequence thereof in a control sample, the correlating step comprises diagnosing a subject with breast cancer; and
(e) administering to the subject a therapeutically effective amount of treatment for the breast cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the probe is one or a plurality of nucleic acid sequences complementary to a nucleic acid sequence chosen from one or a combination of sequences of Table 1, Table 2 and/or Table 3.

### Claim 20 (depends on 19)

The method of claim 19, wherein the one or plurality of probes comprise a fluorophore, a chemiluminescent agent, and/or a quenching agent.

### Claim 21

A method of diagnosing a subject with a benign, pre-malignant, or malignant hyperproliferative cell comprising:
detecting the presence, absence, and/or quantity of one or more oncRNA or functional fragment thereof in a sample from the subject using one or more probe specific for an oncRNA selected from SEQ ID NO:3, SEQ ID NO: 19, SEQ ID NO:32, SEQ ID NO: 40, SEQ ID NO:41, SEQ ID NO: 79, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO: 126, SEQ ID NO: 148 and SEQ ID NO: 191.
